aTENSION.life GmbH

"Democratizing Precision Diagnostics: Accessible Mass Spectrometry" [1]

Where it wins

• Direct Angiotensin II measurement: ALDO+ is the only clinical test that directly and very sensitively determines Angiotensin II, unlike competitors relying on indirect surrogate markers like renin [1].
• Superior analytical performance: Uses LC-MS/MS with internal standardization to provide exact results, avoiding the variability and drug interference common in traditional ELISA-based tests [1].
• High screening accuracy: The Aldosterone-to-Angiotensin II ratio (AA2 ratio) demonstrated 97% sensitivity and 81% specificity for primary aldosteronism screening in validation studies [1].
• Dual clinical utility: Beyond screening for primary aldosteronism, the test provides data on the pharmacological efficacy of existing antihypertensive therapies (ACE inhibitors, ARBs, MRAs) [1].

Credibility: The diagnostic approach is validated by a study published in the journal Hypertension (Burrello et al., 2019) [1].

• Network-Based Diagnostics: Operates a 'Prep ‘n’ Ship™' model that bridges the gap between labs with and without mass spectrometry equipment [1].
• Democratizing Mass Spectrometry: Makes high-end LC-MS/MS diagnostics accessible to all clinical labs by handling the complex analytical part at specialized partner labs [1].
• Scalable Sample Logistics: Referring labs collect and prepare samples on-site, then ship them to partner labs, optimizing workflow and equipment utilization [1].
• Precision Medicine Focus: Provides data to enable personalized anti-hypertensive treatment, moving away from generic trial-and-error approaches [1].

Credibility: The business model is explicitly described as a network solution designed to maximize the utilization of existing mass spectrometry infrastructure [1].

• ELISA-Based Diagnostic Providers: Competitors offering traditional tests that suffer from variability and drug interference [1].
• Other Mass Spectrometry Labs: Reference labs offering LC-MS/MS tests, but potentially lacking the specific ALDO+ platform or network model [1].
• Generic Hypertension Screening Tests: Tests that do not specifically target primary aldosteronism or the RAAS system [1].
• Differentiators: ALDO+ is the only test to directly measure Angiotensin II, offers superior analytical performance, and operates a scalable network model [1].
• Threats: Potential entry of new competitors with advanced diagnostic technologies or changes in clinical guidelines [1].

Credibility: The ALDO+ test's unique features and validation in a peer-reviewed journal provide a strong competitive position [1].

• Undiagnosed Hypertension: High rates of undiagnosed and untreated hypertension, with secondary forms like primary aldosteronism remaining undetected [1].
• Low Screening Rates: Only 1-2% of hypertensive patients are screened for secondary causes, leading to delayed treatment [1].
• Inaccurate Traditional Tests: ELISA-based tests suffer from variability and drug interference, leading to unreliable results [1].
• Trial-and-Error Treatment: Clinicians often manage hypertension without identifying underlying molecular causes, leading to inappropriate medication [1].
• Patient Frustration & Risk: Delayed blood pressure control leads to patient frustration and increased risk of cardiovascular complications [1].

Credibility: The challenge of hypertension screening is well-documented, with low screening rates and limitations of current diagnostic methods [1].

aTENSION.life's network-based model allows for rapid scaling without heavy capital expenditure on equipment. The focus on primary aldosteronism addresses a significant unmet need in hypertension care. The main risk is regulatory approval and reimbursement for the ALDO+ test. The next signal to watch is the adoption rate of the 'Prep ‘n’ Ship™' model by partner labs and the expansion of the network. The opportunity lies in expanding the test to other indications within the RAAS system.

aTENSION.life should prioritize securing regulatory approval and reimbursement codes for the ALDO+ test to ensure widespread adoption. They should invest in clinical education to raise awareness of primary aldosteronism screening among clinicians. Expanding the network to include more partner labs, especially in underserved regions, would increase accessibility. Developing a digital platform for clinicians to order and interpret ALDO+ results would enhance the user experience.